← Back to Clinical Trials
Recruiting NCT06055296

Multisite Implementation of COMPRENDO

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Pediatric Cancer
Sponsor University of California, San Diego
Study Type INTERVENTIONAL
Phase N/A
Enrollment 450
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-01-11
Completion 2028-12-31
Interventions
COMPRENDO Peer Navigation Intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

COMPRENDO (ChildhOod Malignancy Peer Research NavigatiOn) is a multi-site randomized clinical trial (RCT) that uses a Hybrid Type 1 design, to test the effects of a clinical intervention on patient-level outcomes, while exploring multilevel implementation factors that can inform real-world setting implementation. This study will test the impact of COMPRENDO, a peer-navigation intervention, vs. usual care on accrual to childhood cancer therapeutic clinical trials and parental informed consent outcomes. COMPRENDO will be delivered by trained peer navigators in 4 visits. A mixed methods (surveys, individual interviews) implementation evaluation will examine implementation factors that can inform the use of peer navigation in clinical practice, integrating data from clinicians, navigators, administrators, and parents pre and post the RCT.

Eligibility Criteria

Participants (n≈400) will be parents of Hispanic children (0-17 years) with newly diagnosed cancer or cancer-like disease (histiocytic disorders or myelodysplastic syndromes) and eligible for a therapeutic clinical trial who meet the following inclusion criteria: * are a Hispanic parent/primary legal guardian; * has a child aged 0 to 17 y with a new diagnosis of cancer or cancer-like disease (histiocytic disorders or myelodysplastic syndromes); * has a child who is eligible for a therapeutic cancer clinical trial; * will participate in an informed consent discussion for the therapeutic clinical trial; * has an understanding of written and spoken English or Spanish; * has signed the consent form for the proposed COMPRENDO study. Parent Exclusion Criteria: * second malignancy/relapse; * diagnosed at an outside institution; * potential transfer of care to another institution within the next 4 months; * previously on a clinical trial; * does not understand written and spoken English or Spa

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}